Navigation Links
New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies
Date:10/16/2007

SCOTTSDALE, Ariz., Oct. 16 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Anxiety & Depression," physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.

"There have been some notable developments in the use of antipsychotics, and special emphasis on new classes -- including CRF and NK antagonists," according to Jeff Berk, MedPredict President. "The thesis of this panel is that there are two types of new drug launches that will be successful in the next five years. The first is augmentation strategies to SSRIs. Today this includes the use of low dose quetiapine. This time frame should also see the approval of the first NK and CRF antagonists." According to this report, monotherapy strategies will find a home mostly in the primary care setting after failure of a generic SSRI. In the community setting, safety will trump efficacy, and a parity claim with an improved side effect profile will win out.

The report also discusses the role of genomics, endophenotypes and biomarkers in the development of pharmacotherapies for depression.

Drugs/Companies mentioned in this report include: Effexor (venlafaxine; Wyeth), Lexapro (escitalopram; Forest), Pristiq (o-desmethylvenlafaxine; Wyeth), Cymbalta (duloxetine; Lilly), Wellbutrin (bupropion; GlaxoSmithKline), Valdoxan (agomelatine; Novartis/Servier), bifeprunox (Wyeth/Solvay/ Lundbeck), Seroquel (quietiapine; AstraZeneca), amibegron (Sanofi-Aventis), GSK-561679 (GSK), Pexacerfont (BMS-562086; Bristol-Myers Squibb), ONO-2333Ms (Ono), casopitant (GlaxoSmithKline), saredutant (Sanofi-Aventis), esmirtazapine (Organon / Schering-Plough), Nemifitide (Tetragenix), SSR241586 (Sanofi-Aventis), and many others.

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. No harm in reducing prenatal check up to 3 - 6 times says WHO report
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Report on the Safety and Effectiveness of Melatonin supplements
6. WHO report asks for improved healthcare for mother and child
7. Research reports that c-section deliveries are rising
8. Jharkhand reports 13,000 Malaria cases
9. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
10. Experts Insist That Neonatal Herpes Be Reported Regularly
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2016)... ... ... 2 is a set of versatile and smooth logo reveals built exclusively for Final ... a unique logo reveal in just a matter of minutes. Custom settings give the user ... add a uniquely animated logo to any photos or videos. , ProBrand Reveal comes packaged ...
(Date:4/30/2016)... ... 30, 2016 , ... Create an abstract shape animation with ... manipulate three-dimensional shapes with ease all within Apple Motion . Users have ... texture animation, opacity texture animation, overall shape texture displacement, twist, camera controls, and ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor Gardner, President ... today signed a multifaceted agreement which will allow for the research and development ... of Natural and Applied Sciences, Allied Health and Nursing will work together to ...
(Date:4/29/2016)... ... April 30, 2016 , ... World ... the Pick Up Springboard, an automotive invention that improves the storage features of ... worth $162 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System ... Medical Education (ACGME) that it has received accreditation for its residency program on ... residency programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... Directeur Financier Sanofi, leader ... publie ses résultats pour le premier ... Groupe, Jérôme Contamine, commente les résultats ... les perspectives pour le reste de ...
(Date:4/28/2016)... Mich. , April 28, 2016   ... . Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... has signed a definitive agreement to acquire Valley ... Specialty Pharmacy ("TNH"), a leading specialty pharmacy that ... Van Nuys, California . In 2015, TNH ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
Breaking Medicine Technology: